Log in to save to my catalogue

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornit...

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornit...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ac998ae6e1bf48a5a89903e3790cf17a

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma

About this item

Full title

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer Reports, 2022-11, Vol.5 (11), p.e1616-n/a

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background
Survival for patients with high‐risk neuroblastoma (HRNB) remains poor despite aggressive multimodal therapies.
Aims
To study the feasibility and safety of incorporating a genomic‐based targeted agent to induction therapy for HRNB as well as the feasibility and safety of adding difluoromethylornithine (DFMO) to anti‐GD2 immunoth...

Alternative Titles

Full title

A pilot study of genomic‐guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high‐risk neuroblastoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ac998ae6e1bf48a5a89903e3790cf17a

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ac998ae6e1bf48a5a89903e3790cf17a

Other Identifiers

ISSN

2573-8348

E-ISSN

2573-8348

DOI

10.1002/cnr2.1616

How to access this item